PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10192571

Loop ileostomy: technical aspects and complications.

E Carlsen·A B Bergan
View original source ↗Export metadata ↓

Abstract

OBJECTIVE: To study the incidence of complications of construction and closure of loop ileostomies and the final outcome for the patients. DESIGN: Retrospective study. SETTING: University hospital, Norway. SUBJECTS: 100 patients with 103 loop ileostomies, operated on between 1980 and 1990. MAIN OUTCOME MEASURES: Number of complications after ileostomy construction and closure. RESULTS: 7 required re-operation after construction of the loop ileostomy and 11 after its closure. The most common cause was small intestinal obstruction (4 after construction and 6 after closure). 2 developed stomal necrosis. The mean duration of hospital stay was 13 and 10 days for primary and secondary loop ileostomy, respectively, and the mean time before closure was 31 weeks. After closure another 6 developed leaks from the ileal anastomosis that required further operation. Patients with secondary loop ileostomies had their stomas significantly longer than those with primary loop ileostomies (21 compared with 43 weeks, p = 0.00005). CONCLUSION: Despite the number of complications, we think that faecal diversion is still justified in complex pelvic surgery and we should try to reduce the complication rate further.

Explore related subjects

Adenomatous Polyposis ColiColitis, UlcerativeFemaleHumansIleostomyMaleReoperationRetrospective StudiesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Carlsen, A B Bergan. 1999. Loop ileostomy: technical aspects and complications.. https://doi.org/10.1080/110241599750007324

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

[Endometriosis of the transverse colon--a rare localization].

HISTORY: A 65-year-old woman with no complaints came to our hospital for a colonoscopy because of a family history of a colorectal carcinoma. Because of postmenopausal complaints she had been undergoing estrogen therapy for the past five years. INVESTIGATIONS: Colonoscopy revealed a 2 x 2 cm polyp like structure with central tissue proliferation in the transverse colon. Neither chromoendoscopy with indigocarmine nor multiple biopsies indicated an adenomatous glandular proliferation. Miniendosonography revealed the image of a tumour located in the muscularis propria. DIAGNOSIS AND CLINICAL COURSE: As a malign process could not definitely be excluded, a colon segment resection was carried out by laparoscopy. In the operative specimen there was a 2 x 2 cm large tumour growing under the mucosa. Histologically it was an intramural manifestation of an extragenital endometriosis in the area of the muscularis propria with resulting nodular proliferation of the local muscle system. The ectopic endometrial glands in the area of the endometriosis revealed a complex hyperplasia without atypical features, an image suggesting oestrogen stimulation. CONCLUSION: In many cases the diagnosis of an intestinal endometriosis can not be made through a non-invasive diagnostic method such as colonoscopy with biopsy because of the intramural localisation in the muscularis propria. In order to safely rule out a malignant lesion, in unclear cases a resection should be aimed at.

Adenomatous Polyposis Coli↗
PubMed2002

Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation.

Exisulind and its analogues are inhibitors of cyclic GMP phosphodiesterases (PDEs) that have been shown to activate and induce protein kinase G, resulting in the induction of apoptosis in colon cancer cells. These drugs also reduce beta-catenin protein levels and decrease cyclin D1 mRNA levels in SW480 cells. Herein we report on studies pertaining to exisulind regulation of beta-catenin levels and activity in colon tumor cells. Exisulind and its higher-affinity PDE analogues, (Z)-5-fluoro-2-methyl-(4-pyridylidene)-3-(N-benzyl)-indenylacetamide hydrochloride (CP461) and (Z)-1H-indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-[(3,4,5-trimethoxyphenyl)methylene] (CP248), reduced beta-catenin, including the nuclear beta-catenin in SW480 cells (EC(50) approximately 200 microM, 1 microM, and <1 microM, respectively). The 50% reduction of beta-catenin was seen in 8-14 hr. There was no change in beta-catenin mRNA. Exisulind-induced beta-catenin reduction was blocked by the proteasomal inhibitor MG132 (Z-leu-Leu-Leu-CHO), indicating that the effect of exisulind involved ubiquitin-proteasomal degradation. A consequence of reduced beta-catenin in SW480 cells was that exisulind, CP461, and CP248 caused a concentration- and time-dependent decrease in cyclin D1 levels (EC(50) approximately 300 microM, 1 microM, and <1 microM, respectively) in 4 hr. The effect was via decreased cyclin D1 mRNA levels. Exisulind-induced degradation of beta-catenin was not blocked by the inhibition of caspase-3 activity and/or apoptosis, and some SW480 cells showed a reduction in beta-catenin levels before the appearance of early apoptosis indicators. Expression of the N-terminal 170 amino acid fragment of beta-catenin reduced the effects of beta-catenin degradation, cyclin D1 reduction, and the apoptosis response to exisulind. These results indicate that exisulind-induced beta-catenin degradation precedes the induction of apoptosis and that the down-regulation of inappropriate beta-catenin-activated genes accounts in part for the pro-apoptotic effects of exisulind and CP461 in colon tumor cells.

Adenomatous Polyposis Coli↗